lncRNA PCED1B-AS1 facilitates cervical cancer progression via targeting miR-361-3p

Le résumé fourni par la source

In recent years, the incidence of cervical cancer has been on the rise, making it imperative to search for targeted therapeutic tumor-associated biomarkers. PCED1B-AS1 regulates gene expression and affects cell proliferation and differentiation in tumors. However, its function and potential mechanisms in cervical cancer remain unclear. The expression of PCED1B-AS1 in cervical cancer and adjacent tissues was detected by qRT-PCR, and its clinical significance was analyzed by chi-square test and Cox model. The interaction between PCED1B-AS1 and miR-361-3p was verified by ENCORI database, and luciferase reporter assay was used to verify the interaction. The CCK-8 and Transwell assays were used to evaluate their effects on cervical cancer cell function. The expression of PCED1B-AS1 in cervical cancer tissues was significantly higher than that in adjacent tissues, and was significantly correlated with tumor grade, stage, and FIGO classification. The upregulation of PCED1B-AS1 can predict adverse prognosis in cervical cancer patients, and the expression of PCED1B-AS1 is negatively correlated with the expression of miR-361-3p. Silencing PCED1B-AS1 significantly inhibited the growth, migration, and invasion of CaSki and HeLa cells, while inhibition of miR-361-3p could diminish this effect. PCED1B-AS1 is significantly upregulated in cervical cancer tissue, and the regulatory axis formed with miR-361-3p may be involved in tumor progression. Importantly, the high expression of PCED1B-AS1 is significantly associated with poor prognosis in patients, suggesting that it not only serves as a novel molecular biomarker for the diagnosis of cervical cancer but may also provide potential intervention targets for the development of targeted therapeutic strategies.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.